Department of Urology, Mayo Clinic, Rochester, MN.
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Surgical Outcomes Program, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2019 Feb;94(2):262-274. doi: 10.1016/j.mayocp.2018.08.035.
To describe postoperative opioid prescribing practices in a large cohort of patients undergoing urological surgery.
We identified 11,829 patients who underwent 21 urological surgical procedures at 3 associated facilities from January 1, 2015, through December 31, 2016. After converting opioids to oral morphine equivalents (OMEs), prescribing patterns were compared within and across procedures. Subgroup analysis for opioid-naive patients (those without a history of long-term opioid use) was performed. Statistical analysis was utilized to evaluate variations based on demographic and perioperative/postoperative variables.
Of the 11,829 patients, 9229 (78.0%) were prescribed an opioid at discharge, and the median (interquartile range [IQR]) OME prescribed was 188 (150-225). The remaining 9253 patients (78.2%) were considered opioid naive. Striking variation in prescribing patterns was observed within and across surgical procedures. For instance, IQR ranges of 150 or greater were observed for open cystectomy (median, 300; IQR, 210-375], open radical nephrectomy (median, 300; IQR, 225-375), retroperitoneal node dissection (median, 300; IQR, 225-375), hand-assisted laparoscopic nephrectomy (median, 225; IQR, 150-300), and penile prosthesis (median, 225; IQR, 150-315). On multivariate analysis, younger age, cancer diagnosis, and inpatient hospitalization were associated with higher likelihood of receiving a highest-quartile OME prescription for opioid naive patients. Thirty-day refill rates varied from 1.6% to 25.9%. Interestingly, refill rates were higher in patients receiving more opioids at discharge.
The United States is facing an opioid epidemic, and physicians must take action. In this study, we found considerable variation in opioid prescribing patterns within and across surgical procedures. These data provide support for the development of standardized opioid prescribing guidelines for postoperative analgesia.
描述大量接受泌尿外科手术患者的术后阿片类药物处方实践。
我们在 2015 年 1 月 1 日至 2016 年 12 月 31 日期间,从 3 家相关医疗机构中确定了 11829 名接受 21 种泌尿外科手术的患者。将阿片类药物转换为口服吗啡当量(OME)后,在手术程序内和程序之间比较了处方模式。对阿片类药物初治患者(无长期阿片类药物使用史)进行了亚组分析。利用统计分析评估了基于人口统计学和围手术期/术后变量的差异。
在 11829 名患者中,9229 名(78.0%)在出院时开了阿片类药物,中位数(四分位距[IQR])开的 OME 为 188(150-225)。其余 9253 名患者(78.2%)被认为是阿片类药物初治患者。在手术程序内和程序之间观察到处方模式的显著差异。例如,开放式膀胱切除术(中位数 300;IQR,210-375)、开放式根治性肾切除术(中位数 300;IQR,225-375)、腹膜后淋巴结清扫术(中位数 300;IQR,225-375)、手助腹腔镜肾切除术(中位数 225;IQR,150-300)和阴茎假体(中位数 225;IQR,150-315)中观察到 150 或更高 IQR 范围。多变量分析显示,年龄较小、癌症诊断和住院治疗与阿片类药物初治患者接受最高四分位 OME 处方的可能性更高相关。30 天的续药率从 1.6%到 25.9%不等。有趣的是,在出院时接受更多阿片类药物的患者中,续药率更高。
美国正面临阿片类药物流行,医生必须采取行动。在这项研究中,我们发现手术程序内和程序之间的阿片类药物处方模式存在相当大的差异。这些数据为制定术后镇痛的标准化阿片类药物处方指南提供了支持。